Physician profile
Philicia J King
NPI 1528699675
$1,061.68
in general payments reported to CMS, 2019-2025
15 companies · $582 in 2025
The $582 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $295 · 2022: $167 · 2023: $18.23 · 2025: $582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $600.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $165.40 | 2022-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $159.55 | 2022-2025 | Uzedy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $152.52 | 2025 | Abilify Asimtufii, Rexulti |
| Abbvie INC. | $113.61 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $111.17 | 2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $66.53 | 2025 | Caplyta |
| Novo Nordisk INC | $62.45 | 2021 | |
| Esperion Therapeutics, INC. | $49.04 | 2021 | |
| Lilly USA, LLC | $41.99 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $40.35 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $37.30 | 2025 | Cobenfy |
| Allergan, INC. | $26.99 | 2021 | |
| Lundbeck LLC | $15.55 | 2025 | Rexulti |
| Glaxosmithkline, LLC. | $12.34 | 2021 | |
| Genentech USA, INC. | $6.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philicia King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.